How to assess minimally invasive therapies for BPH
March 18, 2020
Kevin McVary, MD, of Loyola University Medical Center in Maywood, IL, provides urologists with tips on how to assess the adoptability of minimally invasive surgical therapies for BPH.
Richard R. Kerr
AUA 2020 annual meeting canceled
March 15, 2020
The 2020 AUA annual meeting has been canceled as a result of the coronavirus (COVID-19) pandemic.
Study will test targeted PCa therapies based on genomic alterations
March 5, 2020
Martin Gleave, MD, of the University of British Columbia in Vancouver, discusses the Genomic Umbrella Neoadjuvant Study (GUNS) trial, which uses a multi-arm, multistage adaptive design to test targeted therapies in patients with high-risk localized disease by matching neoadjuvant therapies to baseline genomic alterations.
Partnership to provide teleurology services to underserved areas
February 13, 2020
The developer of a leading telemedicine platform and a health care staffing agency have teamed up in a pilot program to provide clinical and emergency tele-urology services across the United States.
CTC subtypes: A prognostic marker in GU cancer patients?
January 22, 2020
In a study of circulating tumor cells (CTCs) in metastatic genitourinary cancer patients, shorter survival was associated with high CTC counts at baseline and on therapy, specific CTC morphologic subtypes, PD-L1-positive CTCs, and low percent CD4 and percent CD8 T-cells. Heather Chalfin, MD, discusses the data and explains how CTCs may offer an advantage over other forms of liquid biopsy.
FDA approves enfortumab for locally advanced or metastatic urothelial Ca
January 14, 2020
The FDA has granted accelerated approval to enfortumab vedotin-ejfv (PADCEV) for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before or after surgery or in a locally advanced or metastatic setting.
Pembrolizumab granted new bladder Ca indication
January 14, 2020
The FDA has approved the anti-PD-1 therapy pembrolizumab (KEYTRUDA) as monotherapy for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Enzalutamide approved for metastatic castration-sensitive PCa
December 19, 2019
The FDA has approved a supplemental New Drug Application or enzalutamide (XTANDI) for the treatment of patients with metastatic castration-sensitive prostate cancer.
State of the Specialty survey: Top pain points are revenue drop, prior auth
December 16, 2019
Declining reimbursement for their work and the burden of prior authorization are nearly universal concerns of U.S. urologists, an exclusive Urology Times survey has found.
FDA approves new drug for UTI, two devices for OAB/incontinence
December 4, 2019
November 2019 proved to be a fruitful month for urology-specific FDA approvals, with the agency giving the green light to a new drug for complicated urinary tract infection, an implantable device for the treatment of overactive bladder/retention, and a digital product for strengthening of pelvic floor muscles and treatment of urinary incontinence in women.
